Like any medication, both oral GLP-1 drugs and injections come with potential side effects
Sources MHRA Drug Safety Update Semaglutide (Wegovy, Ozempic and Rybelsus): risk of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION), 5 February 2026 BMJ Semaglutide and NAION, February 2026 Community Pharmacy England MHRA Drug Safety Update: Semaglutide and NAION, 5 February 2026 NowPatient has taken all reasonable steps to ensure that all material is factually accurate, complete, and current
E.WillettW
Alternative weight management strategies, including other pharmacological options or referral to specialist weight management services, should be discussed if Wegovy is discontinued due to intolerable side effects
Patients inject the medication into the abdomen, thigh, or upper arm, rotating injection sites to minimize local reactions